Clinical Trial

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Trial Details
NCT Number NCT07489534
Lead Sponsor Daihong Liu
Conditions Multiple Myeloma
Enrollment 25 participants
Start Date 2025-09-29
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24